Press releases //

IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker

IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.

Link to press (…)  » 

Press releases //

IntegraGen presents positive data from two new studies on miR-31-3p biomarker at ASCO 2015

colorectal-cancer-intgragen-biomarker-mir-31-3p

Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…)  » 

News //

miR-31-3p oncology biomarker data to be presented at ASCO 2015

Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.

The first study will report results from research conducted in cooperation (…)  »